The Evidence on Dopamine Receptor Agonists in the Treatment of Parkinson’s Disease_Chinese Journal of Evidence-Based Medicine

Authors：

 LIU Ming , HAO Zilong

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

LIU Ming, Email: wyplmh@hotmail.com

Keywords：

Dopamine; Dopamine receptor agonists; Parkinson’s disease; Evidence-based medicine

DOI：

10.7507/1672-2531.20100391

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The application of dopamine agonists in Parkinson’s disease has been a hot topic in recent years. Can dopamine receptor agonists serve as the initial drugs for Parkinson’s disease? Does it improve the natural history of patients? Has it neuroprotective role? When and how to use dopamine receptor agonists? This article provides evidence on the pros and cons of dopamine receptor agonists in the treatment of Parkinson’s disease for helping clinical decision making.

Citation： LIU Ming,HAO Zilong. The Evidence on Dopamine Receptor Agonists in the Treatment of Parkinson’s Disease. Chinese Journal of Evidence-Based Medicine, 2010, 10(3): 232-234. doi: 10.7507/1672-2531.20100391 Copy

1.	Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet, 2009, 373(9680): 2055-2066.
2.	中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第二版). 中华神经科杂志, 2009, 42(5): 352-355.
3.	刘鸣, 谢鹏, 主编. 神经内科学. 北京: 人民卫生出版社, 2008.
4.	Stowe RL, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006564. DOI: 10.1002/14651858. CD006564.pub2.
5.	Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord, 2009, 15(4): 287-294.
6.	Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol, 2006, 13(11): 1170-1185.
7.	National Collaborating Centre for Chronic Conditions. Parkinson’s disease. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians, 2006. p. 237.
8.	Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71(7): 474-480.
9.	Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at.
10.	Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287(13): 1653-1661.
11.	Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 2003, 54(1): 93-101.
12.	Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2002, 58(1): 11-17.
13.	刘鸣, 临床个体化处理应尽可能循证决策. 中国循证医学杂志, 2007, 7(2): 83-84.
14.	years. Mov Disord, 2005, 20(2): 190-199.

1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet, 2009, 373(9680): 2055-2066.
2. 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第二版). 中华神经科杂志, 2009, 42(5): 352-355.
3. 刘鸣, 谢鹏, 主编. 神经内科学. 北京: 人民卫生出版社, 2008.
4. Stowe RL, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006564. DOI: 10.1002/14651858. CD006564.pub2.
5. Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord, 2009, 15(4): 287-294.
6. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol, 2006, 13(11): 1170-1185.
7. National Collaborating Centre for Chronic Conditions. Parkinson’s disease. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians, 2006. p. 237.
8. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71(7): 474-480.
9. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at.
10. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287(13): 1653-1661.
11. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 2003, 54(1): 93-101.
12. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2002, 58(1): 11-17.
13. 刘鸣, 临床个体化处理应尽可能循证决策. 中国循证医学杂志, 2007, 7(2): 83-84.
14. years. Mov Disord, 2005, 20(2): 190-199.

Chinese Journal of Evidence-Based Medicine

The Evidence on Dopamine Receptor Agonists in the Treatment of Parkinson’s Disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content